Evidence map›Paper›PMID 25331901›Full record

Trial reportProceedings of the National Academy of Sciences of the United States of America2014

Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season.

Susanne L Linderman, Benjamin S Chambers, Seth J Zost, Kaela Parkhouse, Yang Li, Christin Herrmann, Ali H Ellebedy, Donald M Carter, Sarah F Andrews, Nai-Ying Zheng and 11 more

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 2 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

168 citing papers in PubMed, 2 syntheses or guidelines pooled it, 236 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023-2024 Season.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  20. Article

108 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 2 countries.

Susanne L LindermanWistar Institute, Philadelphia, PA 19104; Institute for Immunology.
Benjamin S ChambersWistar Institute, Philadelphia, PA 19104; Department of Microbiology, and.
Seth J ZostWistar Institute, Philadelphia, PA 19104; Department of Microbiology, and.
Kaela ParkhouseWistar Institute, Philadelphia, PA 19104;
Yang LiWistar Institute, Philadelphia, PA 19104; Department of Microbiology, and.
Christin HerrmannWistar Institute, Philadelphia, PA 19104; Department of Microbiology, and.
Ali H EllebedyEmory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322;
Donald M CarterDepartment of Vaccine and Viral Immunity, Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987;
Sarah F AndrewsDepartment of Medicine, University of Chicago, Chicago, IL 60637;
Nai-Ying ZhengDepartment of Medicine, University of Chicago, Chicago, IL 60637;
Min HuangDepartment of Medicine, University of Chicago, Chicago, IL 60637;
Yunping HuangDepartment of Medicine, University of Chicago, Chicago, IL 60637;
Donna StraussNew York Blood Center, New York, NY 10065;
Beth H ShazNew York Blood Center, New York, NY 10065;
Richard L HodinkaDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; Clinical Virology Laboratory, Children's Hospital of Philadelphia, Philadelphia, PA 19104;
Gustavo Reyes-TeránCenter for Research in Infectious Diseases, National Institute of Respiratory Diseases, 14080 Mexico City, Mexico; and.
Ted M RossDepartment of Vaccine and Viral Immunity, Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987;
Patrick C WilsonDepartment of Medicine, University of Chicago, Chicago, IL 60637;
Rafi AhmedEmory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322;
Jesse D BloomDivision of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109.
Scott E HensleyWistar Institute, Philadelphia, PA 19104; Institute for Immunology, Department of Microbiology, and shensley@wistar.org.
The Wistar Institute · USUniversity of Chicago · USEmory and Henry College · USInstitute of Immunology · HRNew York Blood Center · USVaccine & Gene Therapy Institute of Florida · USChildren's Hospital of Philadelphia · USFred Hutch Cancer Center · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Systems Biological Analysis of Innate and Adaptive Responses to VaccinationU19AI090023 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, LI, SHUZHAO · 2010 to 2021
$45.0M
Toward a Universal Influenza Virus VaccineP01AI097092 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2012 to 2022
$17.6M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
University of Chicago Autoimmunity Center of ExcellenceU19AI082724 · NIAID · UNIVERSITY OF CHICAGO · PI CLARK, MARCUS RAMSAY · 2009 to 2023
$7.2M
Training a New Generation of VaccinologistsT32AI074492 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Benjamin A Lopman · 2009 to 2026
$6.4M
Impact of prior influenza exposures on antibody repertoires to new viral strainsR01AI108686 · NIAID · WISTAR INSTITUTE · PI HENSLEY, SCOTT ERIC · 2014 to 2022
$3.7M
The effect of human pre-exposure history on antigenic drift of influenza virusesR01AI113047 · NIAID · WISTAR INSTITUTE · PI HENSLEY, SCOTT ERIC · 2014 to 2018
$2.5M
Mapping epistasis in molecular evolution: the influenza nucleoproteinR01GM102198 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2012 to 2016
$1.6M
NCI NIH HHS P30 CA010815NCI NIH HHS P30CA010815NCI NIH HHS T32 CA009171NIAID NIH HHS 1P01AI097092-01NIAID NIH HHS 1R01AI108686NIAID NIH HHS 1R01AI113047NIAID NIH HHS P01 AI097092NIAID NIH HHS R01 AI108686NIAID NIH HHS R01 AI113047NIAID NIH HHS T32 AI074492NIAID NIH HHS U19 AI082724NIAID NIH HHS U19 AI090023NIGMS NIH HHS R01 GM102198NIGMS NIH HHS R01GM102198NIH HHS P51 OD011132PHS HHS HSN266200700006C
6 · The paper itself

Abstract

Influenza viruses typically cause the most severe disease in children and elderly individuals. However, H1N1 viruses disproportionately affected middle-aged adults during the 2013-2014 influenza season. Although H1N1 viruses recently acquired several mutations in the hemagglutinin (HA) glycoprotein, classic serological tests used by surveillance laboratories indicate that these mutations do not change antigenic properties of the virus. Here, we show that one of these mutations is located in a region of HA targeted by antibodies elicited in many middle-aged adults. We find that over 42% of individuals born between 1965 and 1979 possess antibodies that recognize this region of HA. Our findings offer a possible antigenic explanation of why middle-aged adults were highly susceptible to H1N1 viruses during the 2013-2014 influenza season. Our data further suggest that a drifted H1N1 strain should be included in future influenza vaccines to potentially reduce morbidity and mortality in this age group.

Indexed as

MutationAdultAnimalsAntigens, ViralFemaleHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesMaleMiceMice, Inbred BALB CMiddle AgedAntigens, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza Vaccinesantibodyantigenic drifthemagglutinininfluenzavaccine

Identifiers

PMID25331901
PMCPMC4226110
OpenAlexW2080224701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.